Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 4 (April)

1. Pathology of breast cancer in women with constitutional CHEK2 mutations.
   Breast Cancer Res Treat, 90(2): 187-9. [Abstract] [Full-text]
2. Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival.
   Breast Cancer Res Treat, 90(2): 169-85. [Abstract] [Full-text]
3. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
   Breast Cancer Res Treat, 90(2): 165-7. [Abstract] [Full-text]
4. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.
   Breast Cancer Res Treat, 90(2): 157-63. [Abstract] [Full-text]
5. Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk.
   Breast Cancer Res Treat, 90(2): 149-55. [Abstract] [Full-text]
6. Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death.
   Breast Cancer Res Treat, 90(2): 139-48. [Abstract] [Full-text]
7. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
   Breast Cancer Res Treat, 90(2): 127-37. [Abstract] [Full-text]
8. Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.
   Breast Cancer Res Treat, 90(2): 117-25. [Abstract] [Full-text]
9. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk.
   Breast Cancer Res Treat, 90(2): 113-5. [Abstract] [Full-text]
10. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.
    Breast Cancer Res Treat, 90(2): 105-12. [Abstract] [Full-text]
11. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion.
    Neoplasia, 7(2): 180-9. [Abstract] [Full-text]
12. Resveratrol and estradiol exert disparate effects on cell migration, cell surface actin structures, and focal adhesion assembly in MDA-MB-231 human breast cancer cells.
    Neoplasia, 7(2): 128-40. [Abstract] [Full-text]
13. Characterization of HER1 (c-erbB1) status in locally advanced breast cancer using fluorescence in situ hybridization and immunohistochemistry.
    Tumour Biol, 26(1): 25-30. [Abstract] [Full-text]
14. Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
    Cancer Res, 65(7): 2840-5. [Abstract] [Full-text]
15. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin.
    Cancer Res, 65(7): 2761-9. [Abstract] [Full-text]
16. Down-regulation of Cx43 by retroviral delivery of small interfering RNA promotes an aggressive breast cancer cell phenotype.
    Cancer Res, 65(7): 2705-11. [Abstract] [Full-text]
17. Gene amplification is a mechanism of Six1 overexpression in breast cancer.
    Cancer Res, 65(7): 2668-75. [Abstract] [Full-text]
18. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Cancer Res, 65(7): 2554-9. [Abstract] [Full-text]
19. Emerging role of RAB GTPases in cancer and human disease.
    Cancer Res, 65(7): 2516-9. [Abstract] [Full-text]
20. Signaling intricacies take center stage in cancer cells.
    Cancer Res, 65(7): 2511-5. [Abstract] [Full-text]
21. Coping style and women's participation in breast and gynecological screening.
    Health Care Women Int, 26(3): 247-61. [Abstract] [Full-text]
22. An integrative review on breast cancer screening practice and correlates among Chinese, Korean, Filipino, and Asian Indian American women.
    Health Care Women Int, 26(3): 225-46. [Abstract] [Full-text]
23. Heightened cortisol responses to daily stress in working women at familial risk for breast cancer.
    Biol Psychol, 69(2): 167-79. [Abstract] [Full-text]
24. Rates of reexcision for breast cancer after magnetic resonance imaging-guided bracket wire localization.
    J Am Coll Surg, 200(4): 527-37. [Abstract] [Full-text]
25. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ.
    J Am Coll Surg, 200(4): 516-26. [Abstract] [Full-text]
26. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice.
    Magn Reson Med, 53(4): 835-42. [Abstract] [Full-text]
27. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40.
    J Biol Chem, 280(14): 13285-91. [Abstract] [Full-text]
28. Natural killer cells and lymphocytes increase in women with breast cancer following massage therapy.
    Int J Neurosci, 115(4): 495-510. [Abstract] [Full-text]
29. Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1.
    Bioorg Med Chem, 13(9): 3141-7. [Abstract] [Full-text]
30. Lack of synergy between estrogen and progesterone on local IGF-I, IGFBP-3 and IGFBP-2 secretion by both hormone-dependent and hormone-independent breast cancer explants in vitro. Effect of tamoxifen and mifepristone (RU 486).
    Growth Horm IGF Res, 15(2): 140-7. [Abstract] [Full-text]
31. Glutathione S-transferase genotypes and cancer risk.
    Cancer Lett, 221(2): 123-9. [Abstract] [Full-text]
32. Ductal breast carcinoma develops through different patterns of chromosomal evolution.
    Genes Chromosomes Cancer, 43(2): 147-54. [Abstract] [Full-text]
33. A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer.
    Br J Cancer, 92(7): 1261-7. [Abstract] [Full-text]
34. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
    J Natl Cancer Inst, 97(7): 533-5. [Abstract] [Full-text]
35. Tumor-host interactions contribute to the elevated expression level of alpha1-antichymotrypsin in metastatic breast tumor xenografts.
    Differentiation, 73(2): 88-98. [Abstract] [Full-text]
36. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Histopathology, 46(4): 431-41. [Abstract] [Full-text]
37. Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin.
    Histopathology, 46(4): 422-30. [Abstract] [Full-text]
38. Second primary malignancies in patients with male breast cancer.
    Br J Cancer, 92(7): 1288-92. [Abstract] [Full-text]
39. Choice of geographic unit influences socioeconomic inequalities in breast cancer survival.
    Br J Cancer, 92(7): 1279-82. [Abstract] [Full-text]
40. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study.
    Br J Cancer, 92(7): 1293-7. [Abstract] [Full-text]
41. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk.
    Br J Cancer, 92(7): 1283-7. [Abstract] [Full-text]
42. Biodegradable dextran-based microspheres for delivery of anticancer drug mitomycin C.
    Biomaterials, 26(26): 5375-85. [Abstract] [Full-text]
43. Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centres.
    J Med Screen, 12(1): 43-9. [Abstract] [Full-text]
44. Validity of process indicators of screening for breast cancer to predict mortality reduction.
    J Med Screen, 12(1): 33-7. [Abstract] [Full-text]
45. Melatonin-estrogen interactions in breast cancer.
    J Pineal Res, 38(4): 217-22. [Abstract] [Full-text]
46. Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain.
    Gene Ther, 12(8): 647-54. [Abstract] [Full-text]
47. Regulation of iodide uptake and sodium/iodide symporter expression in the mcf-7 human breast cancer cell line.
    J Clin Endocrinol Metab, 90(4): 2321-6. [Abstract] [Full-text]
48. The effect of finite patient dimensions and tissue inhomogeneities on dosimetry planning of 192Ir HDR breast brachytherapy: a Monte Carlo dose verification study.
    Int J Radiat Oncol Biol Phys, 61(5): 1596-602. [Abstract] [Full-text]
49. Breast radiotherapy in the lateral decubitus position: A technique to prevent lung and heart irradiation.
    Int J Radiat Oncol Biol Phys, 61(5): 1348-54. [Abstract] [Full-text]
50. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(5): 1337-47. [Abstract] [Full-text]
51. Pattern of local recurrence after conservative surgery and whole-breast irradiation.
    Int J Radiat Oncol Biol Phys, 61(5): 1328-36. [Abstract] [Full-text]
52. Conservative surgery and radiotherapy for stage I/II breast cancer using lung density correction: 10-year and 15-year results.
    Int J Radiat Oncol Biol Phys, 61(5): 1317-27. [Abstract] [Full-text]
53. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    J Clin Oncol, 23(11): 2477-92. [Abstract] [Full-text]
54. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
    J Clin Oncol, 23(11): 2469-76. [Abstract] [Full-text]
55. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.
    J Clin Oncol, 23(11): 2460-8. [Abstract] [Full-text]
56. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
    Cancer Chemother Pharmacol, 55(5): 471-8. [Abstract] [Full-text]
57. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
    Oncologist, 10(4): 242-9. [Abstract] [Full-text]
58. Inducible upregulation of oestrogen receptor-beta1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells.
    J Mol Endocrinol, 34(2): 553-66. [Abstract] [Full-text]
59. Anti-proliferative effect of estrogen in breast cancer cells that re-express ERalpha is mediated by aberrant regulation of cell cycle genes.
    J Mol Endocrinol, 34(2): 535-51. [Abstract] [Full-text]
60. Evidence for the association of synaptotagmin with glutathione S-transferases: implications for a novel function in human breast cancer.
    Clin Biochem, 38(5): 436-43. [Abstract] [Full-text]
61. Biomonitoring of organochlorines in women with benign and malignant breast disease.
    Environ Res, 98(2): 250-7. [Abstract] [Full-text]
62. Motivation for giving birth after breast cancer.
    Psychooncology, 14(4): 282-96. [Abstract] [Full-text]
63. Surviving cancer: a comparison of 5-year disease-free breast cancer survivors with healthy women.
    Psychooncology, 14(4): 307-17. [Abstract] [Full-text]
64. Breast cancer and problems with medical interactions: relationships with traumatic stress, emotional self-efficacy, and social support.
    Psychooncology, 14(4): 318-30. [Abstract] [Full-text]
65. Cimetidine and other histamine2-receptor antagonist use in relation to risk of breast cancer.
    Cancer Epidemiol Biomarkers Prev, 14(4): 1012-5. [Abstract] [Full-text]
66. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.
    Cancer Epidemiol Biomarkers Prev, 14(4): 1008-11. [Abstract] [Full-text]
67. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Cancer Epidemiol Biomarkers Prev, 14(4): 1003-7. [Abstract] [Full-text]
68. Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk.
    Cancer Epidemiol Biomarkers Prev, 14(4): 821-5. [Abstract] [Full-text]
69. Cyp17, urinary sex steroid levels and breast cancer risk in postmenopausal women.
    Cancer Epidemiol Biomarkers Prev, 14(4): 815-20. [Abstract] [Full-text]
70. Lack of association between EBV and breast carcinoma.
    Cancer Epidemiol Biomarkers Prev, 14(4): 809-14. [Abstract] [Full-text]
71. Flavonoids and breast cancer risk in Italy.
    Cancer Epidemiol Biomarkers Prev, 14(4): 805-8. [Abstract] [Full-text]
72. Postmenopausal breast cancer risk and cumulative number of menstrual cycles.
    Cancer Epidemiol Biomarkers Prev, 14(4): 799-804. [Abstract] [Full-text]
73. Retinoic acid receptor-beta2 promoter methylation in random periareolar fine needle aspiration.
    Cancer Epidemiol Biomarkers Prev, 14(4): 790-8. [Abstract] [Full-text]
74. Ki-67 expression in benign breast ductal cells obtained by random periareolar fine needle aspiration.
    Cancer Epidemiol Biomarkers Prev, 14(4): 786-9. [Abstract] [Full-text]
75. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Med Hypotheses, 64(6): 1182-7. [Abstract] [Full-text]
76. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens.
    Int J Gynecol Cancer, 15(2): 240-5. [Abstract] [Full-text]
77. Incidence and clinical significance of lymph node metastasis detected by cytokeratin immunohistochemical staining in ductal carcinoma in situ.
    Ann Surg Oncol, 12(3): 254-9. [Abstract] [Full-text]
78. Prognostic value of extracapsular extension of axillary lymph node metastases in T1 to T3 breast cancer.
    Ann Surg Oncol, 12(3): 246-53. [Abstract] [Full-text]
79. The results of frozen section, touch preparation, and cytological smear are comparable for intraoperative examination of sentinel lymph nodes: a study in 133 breast cancer patients.
    Ann Surg Oncol, 12(2): 173-80. [Abstract] [Full-text]
80. Intraoperative subareolar injection of 99mTc-labeled sulfur colloid results in consistent sentinel lymph node identification.
    Ann Surg Oncol, 12(2): 167-72. [Abstract] [Full-text]
81. Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival.
    Ann Surg Oncol, 12(2): 161-6. [Abstract] [Full-text]
82. A predictive model for the development of hormone-responsive breast cancer.
    Ann Surg Oncol, 12(1): 48-56. [Abstract] [Full-text]
83. Beyond the clinical trials: how often is sentinel lymph node dissection performed for breast cancer?
    Ann Surg Oncol, 12(1): 41-7. [Abstract] [Full-text]
84. Axillary recurrence after sentinel node biopsy.
    Ann Surg Oncol, 12(1): 34-40. [Abstract] [Full-text]
85. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance.
    Ann Surg Oncol, 12(1): 29-33. [Abstract] [Full-text]
86. Can sentinel lymph node biopsy be omitted in patients with favorable breast cancer histology?
    Ann Surg Oncol, 12(1): 24-8. [Abstract] [Full-text]
87. Pentameric procyanidin from Theobroma cacao selectively inhibits growth of human breast cancer cells.
    Mol Cancer Ther, 4(4): 537-46. [Abstract] [Full-text]
88. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
    JAMA, 293(14): 1729-36. [Abstract] [Full-text]
89. Day-case breast cancer axillary surgery.
    Ann R Coll Surg Engl, 87(2): 96-8. [Abstract] [Full-text]
90. Radioguided occult lesion localisation (ROLL) is available in the UK for impalpable breast lesions.
    Ann R Coll Surg Engl, 87(2): 92-5. [Abstract] [Full-text]
91. Women's opinions about attending for breast cancer screening: stability of cognitive determinants during three rounds of screening.
    Br J Health Psychol, 10: 133-49. [Abstract] [Full-text]
92. An application of an extended health belief model to the prediction of breast self-examination among women with a family history of breast cancer.
    Br J Health Psychol, 10: 1-16. [Abstract] [Full-text]
93. Immunotargeted nanoshells for integrated cancer imaging and therapy.
    Nano Lett, 5(4): 709-11. [Abstract] [Full-text]
94. Correlations between access to mammography and breast cancer stage at diagnosis.
    Cancer, 103(8): 1571-80. [Abstract] [Full-text]
95. Cancer, Medicaid enrollment, and survival disparities.
    Cancer, 103(8): 1712-8. [Abstract] [Full-text]
96. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women?
    Cancer, 103(8): 1540-50. [Abstract] [Full-text]
97. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry.
    Cancer, 103(8): 1581-6. [Abstract] [Full-text]
98. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Cancer, 103(8): 1631-43. [Abstract] [Full-text]
99. Breast tumor cell soluble factors induce monocytes to produce angiogenic but not angiostatic CXC chemokines.
    Int J Cancer, 115(3): 429-36. [Abstract] [Full-text]
100. High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells.
     Int J Cancer, 115(3): 403-11. [Abstract] [Full-text]
101. Should oral bisphosphonates be standard of care in women with early breast cancer?
     Breast Cancer Res Treat, 90(3): 315-8. [Abstract] [Full-text]
102. Effect of organ-specific fibroblasts on proliferation and differentiation of breast cancer cells.
     Breast Cancer Res Treat, 90(3): 307-13. [Abstract] [Full-text]
103. Accuracy of breast screening among women with and without a family history of breast and/or ovarian cancer.
     Breast Cancer Res Treat, 90(3): 299-305. [Abstract] [Full-text]
104. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI).
     Breast Cancer Res Treat, 90(3): 295-8. [Abstract] [Full-text]
105. Development of a prolactin receptor-targeting fusion toxin using a prolactin antagonist and a recombinant form of Pseudomonas exotoxin A.
     Breast Cancer Res Treat, 90(3): 281-93. [Abstract] [Full-text]
106. Delayed versus immediate exercises following surgery for breast cancer: a systematic review.
     Breast Cancer Res Treat, 90(3): 263-71. [Abstract] [Full-text]
107. Biomarker profile and genetic abnormalities in lobular carcinoma in situ.
     Breast Cancer Res Treat, 90(3): 249-56. [Abstract] [Full-text]
108. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion.
     Breast Cancer Res Treat, 90(3): 241-7. [Abstract] [Full-text]
109. Women with multiple primary breast cancers diagnosed within a five year period, 1994-1998.
     Breast Cancer Res Treat, 90(3): 223-32. [Abstract] [Full-text]
110. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
     Breast Cancer Res Treat, 90(3): 215-21. [Abstract] [Full-text]
111. Selective sensitivity to wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate of human breast cancer and melanoma cell lines studied in vitro.
     Cancer Detect Prev, 29(2): 155-60. [Abstract] [Full-text]
112. Screening mammography in Minnesota cancer patients.
     Cancer Detect Prev, 29(2): 116-23. [Abstract] [Full-text]
113. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition.
     Mol Immunol, 42(9): 1121-4. [Abstract] [Full-text]
114. Global trends in breast cancer incidence and mortality 1973-1997.
     Int J Epidemiol, 34(2): 405-12. [Abstract] [Full-text]
115. Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.
     Oncogene, 24(16): 2705-14. [Abstract] [Full-text]
116. Breast cancer survival in South Asian women in England and Wales.
     J Epidemiol Community Health, 59(5): 402-6. [Abstract] [Full-text]
117. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
     Mol Cancer Res, 3(4): 203-18. [Abstract] [Full-text]
118. CrkI and CrkII function as key signaling integrators for migration and invasion of cancer cells.
     Mol Cancer Res, 3(4): 183-94. [Abstract] [Full-text]
119. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B.
     Mol Cell Biol, 25(9): 3726-36. [Abstract] [Full-text]
120. SPBP is a phosphoserine-specific repressor of estrogen receptor alpha.
     Mol Cell Biol, 25(9): 3421-30. [Abstract] [Full-text]
121. Comparative analysis of logistic regression and artificial neural network for computer-aided diagnosis of breast masses.
     Acad Radiol, 12(4): 487-95. [Abstract] [Full-text]
122. Associations in breast and colon cancer screening behavior in women.
     Acad Radiol, 12(4): 451-8. [Abstract] [Full-text]
123. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
     Cancer Res, 65(8): 3487-92. [Abstract] [Full-text]
124. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
     Cancer Res, 65(8): 3462-9. [Abstract] [Full-text]
125. Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.
     Cancer Res, 65(8): 3454-61. [Abstract] [Full-text]
126. Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model.
     Cancer Res, 65(8): 3396-403. [Abstract] [Full-text]
127. Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition.
     Cancer Res, 65(8): 3356-63. [Abstract] [Full-text]
128. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone.
     Cancer Res, 65(8): 3209-17. [Abstract] [Full-text]
129. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases.
     Cancer Res, 65(8): 3193-9. [Abstract] [Full-text]
130. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.
     Cancer Res, 65(8): 3179-84. [Abstract] [Full-text]
131. Expression of the Brn-3b transcription factor correlates with expression of HSP-27 in breast cancer biopsies and is required for maximal activation of the HSP-27 promoter.
     Cancer Res, 65(8): 3072-80. [Abstract] [Full-text]
132. Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.
     Cancer Res, 65(8): 3059-62. [Abstract] [Full-text]
133. Linking transcriptional elongation and messenger RNA export to metastatic breast cancers.
     Cancer Res, 65(8): 3011-6. [Abstract] [Full-text]
134. Viscoelastic shear properties of in vivo breast lesions measured by MR elastography.
     Magn Reson Imaging, 23(2): 159-65. [Abstract] [Full-text]
135. Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study.
     QJM, 98(5): 343-8. [Abstract] [Full-text]
136. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
     J Clin Oncol, 23(12): 2822-30. [Abstract] [Full-text]
137. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer.
     J Clin Oncol, 23(12): 2726-34. [Abstract] [Full-text]
138. Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
     J Clin Oncol, 23(12): 2716-25. [Abstract] [Full-text]
139. Electrical impedance scanning for the early detection of breast cancer in young women: preliminary results of a multicenter prospective clinical trial.
     J Clin Oncol, 23(12): 2703-15. [Abstract] [Full-text]
140. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
     J Clin Oncol, 23(12): 2694-702. [Abstract] [Full-text]
141. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
     J Clin Oncol, 23(12): 2686-93. [Abstract] [Full-text]
142. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
     J Clin Oncol, 23(12): 2676-85. [Abstract] [Full-text]
143. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
     Clin Cancer Res, 11(8): 2986-90. [Abstract] [Full-text]
144. Beta1,6-branched oligosaccharides are increased in lymph node metastases and predict poor outcome in breast carcinoma.
     Clin Cancer Res, 11(8): 2969-73. [Abstract] [Full-text]
145. Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer.
     Clin Cancer Res, 11(8): 2962-8. [Abstract] [Full-text]
146. Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
     Clin Cancer Res, 11(8): 2875-8. [Abstract] [Full-text]
147. Aromatase inhibition: translation into a successful therapeutic approach.
     Clin Cancer Res, 11(8): 2809-21. [Abstract] [Full-text]
148. HIC1 promoter methylation and 17p13.3 allelic loss in invasive ductal carcinoma of the breast.
     Cancer Lett, 222(1): 75-81. [Abstract] [Full-text]
149. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece.
     Cancer Lett, 222(1): 57-65. [Abstract] [Full-text]
150. Prolonged skin staining after intradermal use of patent blue in sentinel lymph node biopsy for breast cancer.
     Eur J Surg Oncol, 31(4): 373-5. [Abstract] [Full-text]
151. T1 G1 NO ER positive breast cancer--adjuvant therapy is needed.
     Eur J Surg Oncol, 31(4): 369-72. [Abstract] [Full-text]
152. Sentinel node biopsy is not sensible in breast cancer patients with large primary tumours.
     Eur J Surg Oncol, 31(4): 364-8. [Abstract] [Full-text]
153. Modifications of the learning curve guidelines for breast cancer sentinel node biopsy.
     Eur J Surg Oncol, 31(4): 357-63. [Abstract] [Full-text]
154. The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
     J Surg Res, 125(1): 49-55. [Abstract] [Full-text]
155. Fine needle aspiration cytology of lobular carcinoma in situ on ThinPrep.
     Diagn Cytopathol, 32(5): 276-80. [Abstract] [Full-text]
156. BRCA1 variants in a family study of African-American and Latina women.
     Hum Genet, 116(6): 497-506. [Abstract] [Full-text]
157. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells.
     J Biol Chem, 280(16): 15619-27. [Abstract] [Full-text]
158. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
     J Clin Oncol, 23(12): 2597-605. [Abstract] [Full-text]
159. Transcriptional control of cell density dependent regulation of matrix metalloproteinase and TIMP expression in breast cancer cell lines.
     Thromb Haemost, 93(4): 761-9. [Abstract] [Full-text]
160. Male breast cancer incidence among atomic bomb survivors.
     J Natl Cancer Inst, 97(8): 603-5. [Abstract] [Full-text]
161. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
     J Natl Cancer Inst, 97(8): 595-602. [Abstract] [Full-text]
162. Effects of analogs of indole-3-carbinol cyclic trimerization product in human breast cancer cells.
     Chem Biol Interact, 152(2): 119-29. [Abstract] [Full-text]
163. Breast self-examination and breast awareness: a literature review.
     J Clin Nurs, 14(5): 570-8. [Abstract] [Full-text]
164. Optimization of the accuracy of retention and washout measurements of 99mTc-Sestamibi from breast tumours using an anthropomorphic phantom.
     Phys Med Biol, 50(9): 2113-26. [Abstract] [Full-text]
165. Neonatal effects of breast cancer chemotherapy administered during pregnancy.
     Pharmacotherapy, 25(3): 438-41. [Abstract] [Full-text]
166. Modulation of translation factor's gene expression by histone deacetylase inhibitors in breast cancer cells.
     Clin Chem Lab Med, 43(2): 151-6. [Abstract] [Full-text]
167. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
     Histopathology, 46(5): 561-8. [Abstract] [Full-text]
168. Portrayals of treatment decision-making on popular breast and prostate cancer web sites.
     Eur J Cancer Care (Engl), 14(2): 171-4. [Abstract] [Full-text]
169. Frequency of malignancy in lesions classified as probably benign after dynamic contrast-enhanced breast MRI examination.
     J Magn Reson Imaging, 21(5): 556-64. [Abstract] [Full-text]
170. Subtraction of in-phase and opposed-phase images in dynamic MR mammography.
     J Magn Reson Imaging, 21(5): 565-75. [Abstract] [Full-text]
171. Management of anaemia in patients with breast cancer: role of epoetin.
     Ann Oncol, 16(5): 817-24. [Abstract] [Full-text]
172. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.
     Ann Oncol, 16(5): 726-34. [Abstract] [Full-text]
173. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients.
     Ann Oncol, 16(5): 805-16. [Abstract] [Full-text]
174. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).
     Ann Oncol, 16(5): 707-15. [Abstract] [Full-text]
175. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor.
     Ann Oncol, 16(5): 716-25. [Abstract] [Full-text]
176. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
     Ann Oncol, 16(5): 735-42. [Abstract] [Full-text]
177. Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF.
     Ann Oncol, 16(5): 743-8. [Abstract] [Full-text]
178. Bisphosphonates in breast cancer.
     Ann Oncol, 16(5): 687-95. [Abstract] [Full-text]
179. Single agent versus combination chemotherapy for metastatic breast cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
180. Taxane containing regimens for metastatic breast cancer.
     Cochrane Database Syst Rev. [Abstract] [Full-text]
181. Postirradiation morphea and subcutaneous polyarteritis nodosa: case report and literature review.
     Semin Arthritis Rheum, 34(5): 728-34. [Abstract] [Full-text]
182. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
     Am J Obstet Gynecol, 192(4): 1230-7; discussion 1237-9. [Abstract] [Full-text]
183. Case report: myoepithelial carcinoma of the breast: a case report with imaging and pathological findings.
     Br J Radiol, 78(929): 444-6. [Abstract] [Full-text]
184. Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature.
     Jpn J Clin Oncol, 35(4): 202-6. [Abstract] [Full-text]
185. Emergence of nuclear heparanase induces differentiation of human mammary cancer cells.
     Biochem Biophys Res Commun, 331(1): 175-80. [Abstract] [Full-text]
186. Vascular endothelial growth factor acts as an osteolytic factor in breast cancer metastases to bone.
     Br J Cancer, 92(8): 1531-7. [Abstract] [Full-text]
187. Histopathologic indicators of breast cancer biology: insights from population mammographic screening.
     Br J Cancer, 92(8): 1366-71. [Abstract] [Full-text]
188. Investigation of systemic folate status, impact of alcohol intake and levels of DNA damage in mononuclear cells of breast cancer patients.
     Br J Cancer, 92(8): 1524-30. [Abstract] [Full-text]
189. Model of outcomes of screening mammography: information to support informed choices.
     BMJ, 330(7497): 936. [Abstract] [Full-text]
190. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial.
     BMJ, 330(7497): 932. [Abstract] [Full-text]
191. TGFalpha expression impairs Trastuzumab-induced HER2 downregulation.
     Oncogene, 24(18): 3002-10. [Abstract] [Full-text]
192. Ductal carcinoma in situ of the breast with different histopathological grades and corresponding new breast tumour events: analysis of loss of heterozygosity.
     Acta Oncol, 44(1): 41-9. [Abstract] [Full-text]
193. Aromatase inhibitors in the treatment of early and advanced breast cancer.
     Acta Oncol, 44(1): 23-31. [Abstract] [Full-text]
194. Do bone marrow micrometastases correlate with sentinel lymph node metastases in breast cancer patients?
     J Am Coll Surg, 200(5): 720-5; discussion 725-6. [Abstract] [Full-text]
195. GATA-3 expression as a predictor of hormone response in breast cancer.
     J Am Coll Surg, 200(5): 705-10. [Abstract] [Full-text]
196. The plant polyphenol butein inhibits testosterone-induced proliferation in breast cancer cells expressing aromatase.
     Life Sci, 77(1): 39-51. [Abstract] [Full-text]
197. The causes and treatment of bone loss associated with carcinoma of the breast.
     Cancer Treat Rev, 31(2): 115-42. [Abstract] [Full-text]
198. Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
     Cancer Treat Rev, 31(2): 69-78. [Abstract] [Full-text]
199. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging.
     Cancer, 103(9): 1898-905. [Abstract] [Full-text]
200. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
     Cancer, 103(9): 1763-9. [Abstract] [Full-text]
201. Role of ICAM1 in invasion of human breast cancer cells.
     Carcinogenesis, 26(5): 943-50. [Abstract] [Full-text]
202. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
     Cancer, 103(9): 1770-7. [Abstract] [Full-text]
203. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study.
     Cancer, 103(9): 1778-84. [Abstract] [Full-text]
204. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells.
     J Biol Chem, 280(17): 17163-71. [Abstract] [Full-text]
205. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells.
     J Biol Chem, 280(17): 17480-7. [Abstract] [Full-text]
206. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo.
     Carcinogenesis, 26(5): 968-75. [Abstract] [Full-text]
207. LAF-4 is aberrantly expressed in human breast cancer.
     Int J Cancer, 115(4): 568-74. [Abstract] [Full-text]
208. Anti-HER-3 MAbs inhibit HER-3-mediated signaling in breast cancer cell lines resistant to anti-HER-2 antibodies.
     Int J Cancer, 115(4): 519-27. [Abstract] [Full-text]
209. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
     Carcinogenesis, 26(5): 1000-7. [Abstract] [Full-text]
210. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells.
     Carcinogenesis, 26(5): 900-7. [Abstract] [Full-text]
211. Breast cancer: the role of hormone therapy.
     Semin Reprod Med, 23(2): 167-71. [Abstract] [Full-text]
212. Cross-cultural evaluation of health status using item response theory: FACT-B comparisons between Austrian and U.S. patients with breast cancer.
     Eval Health Prof, 28(2): 233-59. [Abstract] [Full-text]
213. Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound.
     Clin Radiol, 60(5): 573-8. [Abstract] [Full-text]
214. Results of breast conservation therapy from a single-institution community hospital in Hawaii with a predominantly Japanese population.
     Int J Radiat Oncol Biol Phys, 62(1): 193-7. [Abstract] [Full-text]
215. 1998-1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I-II breast cancer.
     Int J Radiat Oncol Biol Phys, 62(1): 183-92. [Abstract] [Full-text]
216. Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy.
     Int J Radiat Oncol Biol Phys, 62(1): 175-82. [Abstract] [Full-text]
217. Increasing mammography screening among low-income African American women with limited access to health information.
     Prev Med, 40(6): 880-7. [Abstract] [Full-text]
218. Baseline predictors of initiation vs. maintenance of regular mammography use among rural women.
     Prev Med, 40(6): 822-30. [Abstract] [Full-text]
219. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials?
     Prev Med, 40(6): 611-8. [Abstract] [Full-text]
220. Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen.
     J Surg Oncol, 90(2): 77-80. [Abstract] [Full-text]
221. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins.
     J Surg Oncol, 90(2): 71-6. [Abstract] [Full-text]
222. Detection and quantification of circulating tumor cells in mouse models of human breast cancer using immunomagnetic enrichment and multiparameter flow cytometry.
     Cytometry A, 65(1): 4-14. [Abstract] [Full-text]
223. A Markov model approach shows a large variation in the length of S phase in MCF-7 breast cancer cells.
     Cytometry A, 65(1): 15-25. [Abstract] [Full-text]
224. Dietary phytoestrogens: potential selective estrogen enzyme modulators?
     Planta Med, 71(4): 287-94. [Abstract] [Full-text]
225. Role of ultrasound in the preoperative staging of patients with breast cancer.
     Eur Radiol, 15(5): 1044-50. [Abstract] [Full-text]
226. Human archival tissues provide a valuable source for the analysis of spatial genome organization.
     Histochem Cell Biol, 123(3): 229-38. [Abstract] [Full-text]
227. Estimating misclassification error with small samples via bootstrap cross-validation.
     Bioinformatics, 21(9): 1979-86. [Abstract] [Full-text]
228. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T.
     Eur Radiol, 15(5): 1037-43. [Abstract] [Full-text]
229. Sections of the nipple and quadrants in mastectomy specimens for carcinoma are of limited value.
     J Clin Pathol, 58(5): 543-5. [Abstract] [Full-text]
230. A novel BRCA2 mutation in an Indonesian family found with a new, rapid, and sensitive mutation detection method based on pooled denaturing gradient gel electrophoresis and targeted sequencing.
     J Clin Pathol, 58(5): 493-9. [Abstract] [Full-text]
231. Pilomatrixoma breast mimicking carcinoma.
     J Coll Physicians Surg Pak, 15(4): 248-9. [Abstract] [Full-text]
232. The ultimate challenge of pregnancy-associated breast carcinoma.
     J Coll Physicians Surg Pak, 15(4): 242-5. [Abstract] [Full-text]
233. Role of imaging in diagnosis of carcinoma of breast.
     J Coll Physicians Surg Pak, 15(4): 238-41. [Abstract] [Full-text]
234. Breast cancer: steroid receptors and other prognostic indicators.
     J Coll Physicians Surg Pak, 15(4): 230-3. [Abstract] [Full-text]
235. Prognostic value of proliferating cell nuclear antigen (PCNA) in infiltrating ductal carcinoma breast.
     J Coll Physicians Surg Pak, 15(4): 225-9. [Abstract] [Full-text]
236. Typing and grading of cytological category C5 breast lesions.
     J Coll Physicians Surg Pak, 15(4): 221-4. [Abstract] [Full-text]
237. Locoregional recurrence after management of carcinoma breast.
     J Coll Physicians Surg Pak, 15(4): 218-20. [Abstract] [Full-text]
238. Sentinel node localization in breast carcinoma.
     J Coll Physicians Surg Pak, 15(4): 215-7. [Abstract] [Full-text]
239. Comparison of fine needle aspiration cytology with excision biopsy of breast lump.
     J Coll Physicians Surg Pak, 15(4): 211-4. [Abstract] [Full-text]
240. Role of FNA cytology in the management of carcinoma breast.
     J Coll Physicians Surg Pak, 15(4): 207-10. [Abstract] [Full-text]
241. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
     J Coll Physicians Surg Pak, 15(4): 204-6. [Abstract] [Full-text]
242. Toxicity profile and objective response of paclitaxel in metastatic breast cancer.
     J Coll Physicians Surg Pak, 15(4): 200-3. [Abstract] [Full-text]
243. Cytohistopathological correlation of C3 and C4 breast lesions.
     J Coll Physicians Surg Pak, 15(4): 196-9. [Abstract] [Full-text]
244. Psychological and genetic counseling implications for adolescent daughters of mothers with breast cancer.
     Clin Genet, 67(6): 481-91. [Abstract] [Full-text]
245. Bootstrap methods for statistical inference from stereological estimates of volume fraction.
     J Microsc, 218: 160-70. [Abstract] [Full-text]
246. Sexual minority women's coping and psychological adjustment after a diagnosis of breast cancer.
     J Womens Health (Larchmt), 14(3): 214-24. [Abstract] [Full-text]
247. Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early-onset breast cancer.
     Genet Test, 9(1): 48-53. [Abstract] [Full-text]
248. Current realities of delivering mammography services in the community: do challenges with staffing and scheduling exist?
     Radiology, 235(2): 391-5. [Abstract] [Full-text]
249. Accuracy of segmentation of a commercial computer-aided detection system for mammography.
     Radiology, 235(2): 385-90. [Abstract] [Full-text]
250. Trends in recall, biopsy, and positive biopsy rates for screening mammography in an academic practice.
     Radiology, 235(2): 396-401. [Abstract] [Full-text]
251. Randomized trial of hyperthermia and radiation for superficial tumors.
     J Clin Oncol, 23(13): 3079-85. [Abstract] [Full-text]
252. Depression, correlates of depression, and receipt of depression care among low-income women with breast or gynecologic cancer.
     J Clin Oncol, 23(13): 3052-60. [Abstract] [Full-text]
253. Patterns and correlates of local therapy for women with ductal carcinoma-in-situ.
     J Clin Oncol, 23(13): 3001-7. [Abstract] [Full-text]
254. Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer.
     J Clin Oncol, 23(13): 2996-3000. [Abstract] [Full-text]
255. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study.
     J Clin Oncol, 23(13): 2988-95. [Abstract] [Full-text]
256. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
     J Clin Oncol, 23(13): 2980-7. [Abstract] [Full-text]
257. Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies.
     J Steroid Biochem Mol Biol, 93(2): 257-62. [Abstract] [Full-text]
258. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
     J Steroid Biochem Mol Biol, 93(2): 249-56. [Abstract] [Full-text]
259. Are aromatase inhibitors superior to antiestrogens?
     J Steroid Biochem Mol Biol, 93(2): 237-47. [Abstract] [Full-text]
260. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
     J Steroid Biochem Mol Biol, 93(2): 221-36. [Abstract] [Full-text]
261. The role of progesterone metabolites in breast cancer: potential for new diagnostics and therapeutics.
     J Steroid Biochem Mol Biol, 93(2): 201-8. [Abstract] [Full-text]
262. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
     J Steroid Biochem Mol Biol, 93(2): 191-200. [Abstract] [Full-text]
263. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
     J Steroid Biochem Mol Biol, 93(2): 173-82. [Abstract] [Full-text]
264. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells.
     Oncogene, 24(19): 3177-86. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.